• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    3/7/25 5:03:10 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false000160796200-0000000Floor 6Yokneam IlitIL+508.251.11544.959.0123Ordinary Shares, par value NIS 0.2500016079622025-03-072025-03-07


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): March 7, 2025
     
    Lifeward Ltd.

    (Exact Name of Registrant as Specified in its Charter)
      
    Israel
     
    001-36612
     
    Not Applicable
    (State or Other Jurisdiction of Incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    200 Donald Lynch Blvd. Marlborough, MA
     
    01752
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154
      
    Not Applicable
    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol
     
    Name of each exchange on which registered
    Ordinary Shares, par value NIS 1.75
     
    LFWD
     
    NASDAQ

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 1.01
    Entry into a Material Definitive Agreement.

    On March 7, 2025, Lifeward Ltd. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time at its sole discretion, its ordinary shares, par value NIS 1.75 (“Ordinary Shares”), through or to Wainwright, acting as sales agent or principal. The issuance and sale, if any, of Ordinary Shares under the ATM Agreement will be made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-263984), which was filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on March 30, 2022, and declared effective on May 16, 2022, the base prospectus included therein and the related prospectus supplement (the “Prospectus Supplement”) filed by the Company with the SEC on March 7, 2025. In accordance with the terms of the ATM Agreement, under the Prospectus Supplement, the Company may offer and sell its Ordinary Shares having an aggregate offering price of up to $5,488,800 from time to time through or to Wainwright.

    The Company is not obligated to sell any shares under the ATM Agreement. Each time the Company wishes to issue and sell shares under the ATM Agreement, the Company will notify Wainwright of the number of shares to be issued, the dates on which such sales may be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Unless Wainwright declines to accept the terms of such notice, subject to the terms and conditions of the ATM Agreement, Wainwright has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such shares up to the amount specified on such terms. Under the ATM Agreement, Wainwright may sell the Company’s Ordinary Shares by any method permitted by law that is deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) promulgated under the U.S. Securities Act of 1933, as amended, including, without limitation, sales made directly on or through the Nasdaq Capital Market or any other existing trading market in the United States for the Ordinary Shares, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as principal, in privately negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. The Company will pay Wainwright in cash a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse certain legal fees and disbursements and provide Wainwright with customary indemnification and contribution rights against certain liabilities. The ATM Agreement may be terminated by the Company at any time upon ten (10) business day’s prior written notice to Wainwright, or by Wainwright at any time.

    The foregoing description of the ATM Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the ATM Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

    The representations, warranties and covenants contained in the ATM Agreement were made solely for the benefit of the parties to the ATM Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the ATM Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the ATM Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

    A copy of the legal opinion of Goldfarb Gross Seligman & Co. relating to the Ordinary Shares issuable under the ATM Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares, nor shall there be any offer, solicitation or sale of such shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    Item 9.01
    Financial Statements and Exhibits.
    (d) Exhibits
     
    Exhibit No.
    Description
    5.1
    Opinion of Goldfarb Gross Seligman & Co.
    10.1
    At The Market Offering Agreement, dated March 7, 2025, by and between the Company and H.C. Wainwright & Co., LLC.
    23.1
    Consent of Goldfarb Gross Seligman & Co. (contained in Exhibit 5.1).
    104
    Cover Page Interactive Date File (embedded within the Inline XBRL document).
     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Lifeward Ltd.
     
     
     
    Date: March 7, 2025
    By:
    /s/ Mike Lawless
     
     
    Mike Lawless
     
     
    Chief Financial Officer


    Get the next $LFWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Leadership Updates

    Live Leadership Updates

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

      11/7/24 4:05:14 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

      9/10/24 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Financials

    Live finance-specific insights

    See more
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (

      5/7/25 4:30:25 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

      2/28/25 8:00:16 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    SEC Filings

    See more
    • Lifeward Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Lifeward Ltd. (0001607962) (Filer)

      5/19/25 8:40:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form S-3 filed by Lifeward Ltd.

      S-3 - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 4:06:12 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Lifeward Ltd.

      10-Q - Lifeward Ltd. (0001607962) (Filer)

      5/15/25 9:00:43 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifeward Names Mark Grant as New CEO

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

      5/19/25 8:30:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward to Present at Sidoti Virtual Investor Conference on May 21

      MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, Chief Executive Officer, will make a corporate presentation and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May 21-22, 2025. Joining him will be Mike Lawless, Chief Financial Officer. The presentation will begin at 10:00 AM EDT on May 21, 2025 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_5U4M2xfKTV2ItMDBl

      5/19/25 6:00:00 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Lifeward Ltd. Reports First Quarter 2025 Financial Results

      U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

      5/15/25 8:00:33 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/27/24 8:03:53 AM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      11/26/24 7:07:36 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Lifeward with a new price target

      Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

      2/10/25 7:00:44 AM ET
      $LFWD
      Industrial Specialties
      Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lind Global Fund Ii Lp sold $1,655,009 worth of Ordinary Shares (573,110 units at $2.89) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      1/8/25 5:20:52 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Richner Randel sold $7,214 worth of Ordinary Shares (4,285 units at $1.68) (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 4:08:29 PM ET
      $LFWD
      Industrial Specialties
      Health Care
    • Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

      4 - Lifeward Ltd. (0001607962) (Issuer)

      12/17/24 8:55:09 AM ET
      $LFWD
      Industrial Specialties
      Health Care